Oxycodone HCl 20 mg

Product Description

Oxycodone Hydrochloride 20 mg oral tablets deliver an immediate-release pure opioid analgesic engineered for rapid pain intervention. Indicated for acute, severe episodic pain refractory to non-opioid multimodal analgesia, oxycodone exerts its primary therapeutic action by modulating sensory and emotional pain processing within the central nervous system.

Clinical Profile & Pharmacodynamics

• Active Ingredient: Oxycodone Hydrochloride (20 mg)

• Mechanism of Action: Functions as a full agonist at $\mu$-opioid receptors located throughout the brain and spinal cord. Binding triggers G-protein-coupled receptor activation, inhibiting adenylyl cyclase, closing voltage-sensitive calcium channels, and stimulating inwardly rectifying potassium conductance. This cellular hyperpolarization dampens presynaptic neurotransmitter release (such as substance P and glutamate) and attenuates ascending nociceptive signaling.

• Pharmacokinetics & Absorption: Rapidly absorbed from the gastrointestinal tract, achieving peak plasma concentrations ($C_{\max}$) within 1.0 to 1.5 hours post-administration. Demonstrates an oral bioavailability of approximately 60% to 87% with an effective analgesic duration of 3 to 6 hours.

• Metabolism & Clearance: Extensively metabolized hepatically via cytochrome P450 enzymes—predominantly CYP3A4 to noroxycodone and CYP2D6 to oxymorphone—with a terminal elimination half-life averaging 3.2 hours followed by primary renal excretion.

Indications & Clinical Use Guidelines

• Severe Acute Pain Management: Prescribed for the short-term management of acute post-operative, trauma-related, or episodic breakthrough pain requiring high-potency opioid intervention where non-opioid treatments fail to provide adequate relief.

• Dosing Protocols: Therapy must be individualized and titrated to the lowest effective dose for the shortest duration possible to mitigate tolerance, dependence, and respiratory depression risks.

Important Safety Information & Boxed Warnings

• Addiction, Abuse, and Misuse: Oxycodone is a Schedule II controlled substance carrying high risks of misuse, abuse, physical dependence, and diversion, which can lead to life-threatening overdose and death.

• Life-Threatening Respiratory Depression: Serious, life-threatening, or fatal respiratory depression may occur, with the highest risk present upon initiation or dose escalation. Carbon dioxide retention from opioid-induced respiratory depression can exacerbate intracranial pressure.

• Accidental Ingestion Risk: Accidental ingestion of even one 20 mg dose, particularly by children, can cause fatal respiratory arrest. Store securely in a dedicated lockbox.

• Concomitant Use with Benzodiazepines & CNS Depressants: Co-administration with benzodiazepines, tranquilizers, sedatives, or alcohol significantly elevates the risk of profound sedation, respiratory collapse, coma, and mortality.

• CYP3A4 Drug Interactions: Concomitant use with CYP3A4 inhibitors may cause dangerous increases in oxycodone plasma levels, whereas discontinuation of CYP3A4 inducers can precipitate acute toxicity.